Intuitive Surgical (NASDAQ:ISRG) SVP Mark Brosius Sells 648 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 648 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $488.10, for a total value of $316,288.80. Following the transaction, the senior vice president owned 5,916 shares in the company, valued at $2,887,599.60. The trade was a 9.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mark Brosius also recently made the following trade(s):

• On Thursday, March 5th, Mark Brosius sold 648 shares of Intuitive Surgical stock. The shares were sold at an average price of $495.20, for a total value of $320,889.60.
• On Wednesday, March 4th, Mark Brosius sold 2,362 shares of Intuitive Surgical stock. The shares were sold at an average price of $498.68, for a total transaction of $1,177,882.16.
• On Monday, December 15th, Mark Brosius sold 464 shares of Intuitive Surgical stock. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36.
• On Friday, December 12th, Mark Brosius sold 4,500 shares of Intuitive Surgical stock. The shares were sold at an average price of $547.36, for a total value of $2,463,120.00.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded down $9.63 on Friday, reaching $487.07. 984,254 shares of the company’s stock were exchanged, compared to its average volume of 2,032,338. The stock has a fifty day simple moving average of $523.39 and a 200-day simple moving average of $511.99. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $603.88. The firm has a market cap of $172.97 billion, a price-to-earnings ratio of 61.73, a P/E/G ratio of 3.86 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.72 billion. During the same period last year, the firm earned $2.21 EPS. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SteelPeak Wealth LLC boosted its stake in shares of Intuitive Surgical by 28.7% during the 3rd quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock valued at $18,781,000 after buying an additional 9,364 shares during the period. Atlantic Union Bankshares Corp raised its holdings in shares of Intuitive Surgical by 19.3% during the third quarter. Atlantic Union Bankshares Corp now owns 22,759 shares of the medical equipment provider’s stock worth $10,179,000 after acquiring an additional 3,676 shares in the last quarter. World Investment Advisors boosted its position in Intuitive Surgical by 238.3% during the third quarter. World Investment Advisors now owns 5,399 shares of the medical equipment provider’s stock valued at $2,415,000 after purchasing an additional 3,803 shares during the last quarter. E. Ohman J or Asset Management AB boosted its position in Intuitive Surgical by 4.1% during the third quarter. E. Ohman J or Asset Management AB now owns 28,306 shares of the medical equipment provider’s stock valued at $12,659,000 after purchasing an additional 1,123 shares during the last quarter. Finally, Valley Wealth Managers Inc. grew its stake in Intuitive Surgical by 52.7% in the third quarter. Valley Wealth Managers Inc. now owns 4,084 shares of the medical equipment provider’s stock valued at $1,826,000 after purchasing an additional 1,409 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ISRG. BTIG Research reissued a “buy” rating and issued a $616.00 price objective on shares of Intuitive Surgical in a report on Friday, January 23rd. The Goldman Sachs Group reiterated a “buy” rating and set a $714.00 price target on shares of Intuitive Surgical in a report on Friday, January 9th. Argus cut their target price on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Robert W. Baird lowered their price objective on shares of Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, UBS Group set a $570.00 price target on shares of Intuitive Surgical and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $615.86.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.